The role of CD36 in the effect of arginine in atherosclerotic rats

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 1494-1499

  Wang, Xin ^a   Wei, Jianming ^a   Pan, Lijian ^a   Shi, Yijun ^a   Lin, Haihong ^a   Gong, Hui ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antigens, CD36; Arginine; Atherosclerosis

Indexed keywords

ARGININE; CD36 ANTIGEN; SIMVASTATIN; CD36 PROTEIN, RAT;

ADULT; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; AORTA; DIETARY SUPPLEMENT; INTIMA; LIPID DIET; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY;

ANIMALS; ANTIGENS, CD36; AORTA; ARGININE; ATHEROSCLEROSIS; BLOTTING, WESTERN; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TUNICA INTIMA;

EID: 84982307171     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893388     Document Type: Article

References (25)

1. Andreoli TE, Carpenter CC, Griggs RC: Cecil Essentials of Medicine. Peking University Medical Press, Peking; 2008
2. Schächinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long term outcome of coronary heart disease. Circulation, 2000; 101: 1899–906
3. Li CQ, Wogan GN: Nitric oxide as a modulator of apoptosis. Cancer Lett, 2005; 226: 1–15
4. Tricot O, Mallat Z, Heymes C et al: Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation, 2000; 101: 2450–53
5. Napoli C, Ignarro LJ: Nitric oxide-releasing drugs. Annu Rev Pharmacol Toxicol, 2003; 43: 97–123
6. Flammer AJ, Lüscher TF: Three decades of endothelium research: from the detection of nitric oxide to the everyday implementation of endothelial function measurements in cardiovascular diseases. Swiss Med Wkly, 2010; 140: w13122
7. Fiorito C, Balestrieri ML, Crimi E et al: Effect of L-arginine on circulating endothelial progenitor cells and VEGF after moderate physical training in mice. Int J Cardiol, 2008; 126: 421–23
8. Kawano H, Motoyama T, Hirai N et al: Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: possible role of oxidative stress. Atherosclerosis, 2002; 161: 375–80
9. Toth PP, Ballantyne CM, Davidson MH et al: Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol, 2012; 6: 180–91
10. Mierzecki A, Kłoda K, Bukowska H et al: Association between low-dose folic acid supplementation and blood lipids concentrations in male and female subjects with atherosclerosis risk factors. Med Sci Monit, 2013; 19: 733–39
11. Wang X, Pu H, Ma C et al: Adiponectin abates atherosclerosis by reducing oxidative stress. Med Sci Monit, 2014; 20: 1792–800
12. Javanmard SH, Gheisari Y, Soleimani M et al: Effect of L-arginine on circulating endothelial progenitor cells in hypercholesterolemic rabbits. Int J Cardiol, 2010; 143: 213–16
13. Chin-Dusting JP, Willems L, Kaye DM: L-Arginine transporters in cardiovascular disease: A novel therapeutic target. Pharmacol Ther, 2007; 116: 428–36
14. Gad MZ, Abu El Maaty MA, El-Maraghy SA et al: Investigating the cardioprotective abilities of supplemental L-arginine on parameters of endothelial function in a hypercholesterolemic animal model. J Nutr Sci Vitaminol (Tokyo), 2014; 60: 145–51
15. Dhar I, Dhar A, Wu L, Desai K: Arginine attenuates methylglyoxal- and high glucose-induced endothelial dysfunction and oxidative stress by an endothelial nitric-oxide synthase-independent mechanism. J Pharmacol Exp Ther, 2012; 342: 196–204
16. Sourij H, Meinitzer A, Pilz S et al: Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. Atherosclerosis, 2011; 218: 220–25
17. Shen W, Bai YY, Zhang XX, Wang YF: L-Arginine improves endothelial function of brachial artery. J Clin Cardiol, 2006; 22: 653–55
18. Matsumoto K, Hirano K, Nozaki S et al: Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor gamma, which regulates gain of Mphilike phenotype in vitro, and its implication in atherogenesis. Arterioscler Thromb Vasc Biol, 2000; 20: 1027–32
19. Robertson S, Colombo ES, Lucas SN et al: CD36 mediates endothelial dysfunction downstream of circulating factors induced by O3 exposure. Toxicol Sci, 2013; 134: 304–11
20. Park YM: CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med, 2014; 46: e99
21. Rubic T, Lorenz RL: Downregulated CD36 and oxLDL up take and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of inter-leukin 210. Cardiovasc Res, 2006; 69: 527–35
22. Ferreira V, van Dijk KW, Groen AK et al: Macrophage specific inhibition of NF-kappaB activation reduces foam-cell formation. Atherosclerosis, 2007; 192: 283–90
23. Han J, Zhou X, Yokoyama T et al: Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD 36. Circulation, 2004; 109: 790–96
24. Puccetti L, Sawamura T, Pasqui AL et al: Atorvastatin reduces platelet2oxidized2 LDL receptor ex ression in hypercholesterolaemic patients. Eur J Clin Invest, 2005; 35: 47–51
25. Aji W, Ravalli S, Szabolcs M et al: L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation, 1997; 95: 430–37